tbuckley/cabot-search huggingface dataset:
The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.
Authors: Tom E. Howard, Shelley A. Cole, Carol K. Kasper, Afshin Ameri, Kavita Natarajan, Raymond G. Watts, Valrie A. Manard, Shelley M. Nakaya, Christine L Kempton, Martina Kennedy, Benjamin Kim, Rathi V. Iyer, Laura Almasy
Journal: Blood (2009)
Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases.
Authors: Elizabeth H. Stover, Jing Chen, Cedric Folens, Benjamin H. Lee, Nicole Mentens, Peter Marynen, D. Gary Gilliland, Jan Cools
Journal: Blood (2005)
Developed nations should set an example on accepting funds from infant formula companies
Authors: Sam Ebenezer Athikarisamy
Journal: BMJ (2016)

At medical school we were taught to stay away from infant formula companies. Despite strict regulations from the paediatric associations, the companies kept coming back to us under the pretence of conducting quizzes. In a remote hospital where I worked, the gatekeeper would not allow representatives in if he learnt that they …
Kinetics of Engraftment and Predictors of Outcome in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL) After Treatment with Low Dose Total Body Irradiation (TBI) Followed by related or unrelated hematopoietic Stem Cell Transplantation
Authors: Karin Hebenstreit, Simona Iacobelli, Ann-Kathrin Eisfeld, Christian Pfrepper, Thoralf Lange, Rainer Krahl, Haifa K. Al-Ali, Cornelia Becker, Wolfram Pönisch, Gerhard Behre, Dietger Niederwieser
Journal: Blood (2011)
Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAII)
Authors: Paola Bianchi, Klaus Schwarz, Elisa Fermo, Katja Heinrich, Cristina Vercellati, Anna Paola Maria Luisa Marcello, Richard van Wijk, Rob van Zwieten, Laura Banov, Antonella Sau, Walter A. Wuillemin, Stephen Opat, Wilma Barcellini, Hermann Heimpel, Alberto Zanella
Journal: Blood (2010)
Doctor struck off for misconduct is allowed back on medical register
Authors: Clare Dyer
Journal: BMJ (2016)

A doctor who was struck off seven years ago by a fitness to practise panel of the General Medical Council for dishonesty in a job application has been reinstated by the Medical Practitioners Tribunal Service, the body that in 2012 took over the task of disciplining doctors.

It is rare but not impossible for a doctor to win back a place on the medical register after erasure for misconduct. Mohamad Kataya has become the 10th in five and a half years to do so.

Kataya, who qualified …
ATIM-04. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM
Authors: David Reardon, Thomas Kaley, Jorg Dietrich, Michael Lim, Gavin Dunn, Hui Gan, Timothy Cloughesy, Jennifer Clarke, Andrew Park, Mary Macri, Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Venhaus
Journal: Neuro-Oncology (2016)

DUR is a human IgG1 mAb against PD-L1. Blockade of PD-1/PD-L1 has shown benefit among solid tumors; data implicate PD-1/PD-L1 signaling as a significant contributor to immunosuppression in GBM. BEV is an approved angiogenesis inhibitor for recurrent GBM; angiogenesis inhibition may promote antitumor benefit of immunotherapies. This ongoing Phase 2 open-label study (NCT02336165) evaluates the safety and efficacy of DUR (10 mg/kg Q2W) in 5 GBM cohorts. This report presents safety and efficacy for Cohort B (BEV-naïve recurrent GBM; DUR monotherapy). The primary efficacy endpoint for Cohort B is progression-free survival at 6 months (PFS-6), based on modified RANO by investigator assessment; secondary endpoints include safety/tolerability. A PFS-6 of 10% is the comparative historical benchmark (pre-BEV). The null hypothesis (PFS-6 ≤ 10%) was tested in the Intent-to-Treat (ITT) population against the alternative hypothesis (α=0.05, 90% confidence interval [CI]). ITT includes patients receiving any dose of DUR and having at least baseline and 1 post-baseline tumor assessment. First patient dosed: 05Mar2015; data cutoff: 05Feb2016. Cohort B completed enrollment of 31 patients (male: 83.9%; mean age: 54.0 [24-77] years; baseline ECOG PS0: 51.6%, PS1: 48.4%; baseline measurable lesions: 77.4%). Incidences of treatment-related adverse events (TRAEs) by maximum CTCAE grade (Gr) were Gr1: 35.5%; Gr2: 41.9%; Gr3: 9.7%; and Gr4/5: 0%. Most common TRAEs (≥3 (9.7%) patients): fatigue, headache, hemiparesis, increased AST, and decreased platelets, WBCs and lymphocytes. Thirty patients were evaluable for efficacy (PFS, objective response rate [ORR]); 6 were progression free at 6 months. Kaplan-Meier estimate for PFS-6 was 20.0% (90% CI: 9.7, 33.0). ORR: partial response, 5 (16.7%) patients; stable disease, 13 (43.3%). DUR monotherapy appears to be well tolerated and shows activity in BEV-naïve recurrent GBM. Further studies are warranted.
RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma
Authors: Hans Lee, Hua Wang, Heather Lin, Veera Baladandayuthapani, Jin He, Richard Julian Jones, Isere Kuiatse, Dongmin Gu, Zhiqiang Wang, Sean O'Brien, Jonathan J Keats, Jing Yang, Richard Eric Davis, Robert Z. Orlowski
Journal: Blood (2015)
Cultural group selection in the light of the selection of extended behavioral patterns
Authors: Carsta Simon
Journal: Behavioral and Brain Sciences (2016)

Abstract The cultural group selection hypothesis is supported by considerations of short-term and long-term behavioral patterns of group members, and the short-term and long-term consequences of that behavior. The key to understanding cooperation lies in understanding that the effect of an extended behavioral pattern does not equal – and might even be opposite to – the added effects of its parts.
Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy Versus LMWHs and Display Improved Hemodynamic Responses as Compared to Protamine
Authors: Richard W. Scott, Michael J. Costanzo, Katie B. Freeman, Robert W. Kavash, Trevor M. Young, William F. DeGrado, Walter Jeske
Journal: Blood (2010)
Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma.
Authors: Patrick Michael Dillon, Chris Moskaluk, Paula M. Fracasso, Gina R. Petroni, Christopher Y. Thomas
Journal: Journal of Clinical Oncology (2013)

6021 Background: Adenoid cystic carcinoma (ACC) is an uncommon malignancy of secretory glands for which there is no standard systemic therapy. At least 90% of ACC tumors carry a t(6;9)(q22–23;p23–24) chromosome translocation that results in overexpression of the MYB oncogene that in turn upregulates FGF2 and other growth factors. Dovitinib is a multiple receptor kinase inhibitor that could potentially block autocrine activation of the FGFR and VEGFR-mediated angiogenesis. In a mouse model, dovitinib suppressed the growth of low passage ACC xenografts. Methods: In this open-label, single-arm trial, patients (n=21) with metastatic ACC that progressed in the last 6 months were treated with dovitinib 500 mg/d, 5-days on/2-days off. The primary endpoint was objective response rate using a two-stage design to test a null and alternative rate of 1% and 18%, respectively, with 90% power and type I error &lt;5%. Secondary endpoints were progression-free survival, safety, quality of life, biomarker studies, and change in tumor growth rate. Results: All 21 patients (median age 54.3, range 29-74) had previous treatment with chemotherapy, radiotherapy or targeted agents. Median duration of treatment to date is 5.7 months (range 2-10 months) and is ongoing in 11 patients. Nine of 21 patients required dose reductions. Grade 3/4 drug-related adverse events included thromboembolism (4), hematuria (1), dehydration (1), pneumonia (2), hypertriglyceridemia (3), diarrhea (2), stomach pain (2), anxiety (1), transaminitis (3) and cytopenias (4). One death occurred unrelated to study drug. Among 19 evaluable patients, 2 had partial responses by RECIST criteria (1 with lung metastases and 1 with tracheal recurrence and stable bone metastases). Both experienced improvements in pain ratings and are free of disease progression at 8+ and 5+ months. Stable disease &gt;6 months was observed in 9 patients while 6 others with shorter follow-up have not progressed. Four patients progressed early (&lt;4 months) and two are too early to assess. Conclusions: Dovitinib produces objective partial responses and prolonged tumor stabilization with acceptable toxicity in patients with progressive ACC. Clinical trial information: NCT01524692.
Recurrent 6pLOH Is the Most Common Somatic Lesion in Refractory Cytopenia of Childhood and Occurs Very Infrequently in Severe Aplastic Anemia
Authors: Marcin W Wlodarski, Shinsuke Hirabayashi, Brigitte Strahm, Sandra Urbaniak, Brigitte Schlegelberger, Ingrid Furlan, Alexandra Fischer, Wilfried Truckenmüller, Ayami Yoshimi-Noellke, Peter Noellke, Irith Baumann, Charlotte M Niemeyer
Journal: Blood (2012)
Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (&gt;200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.
Authors: Caroline Hastings, Harland N. Sather, Nita L. Seibel, James Nachman, Peter G. Steinherz, Kathy Bertolone, Cynthia DeLaat, Lawrence J. Ettinger, Janet Franklin, David Robert Freyer, Leonard A. Mattano, Torrey L. Mitchell, Charles M. Rubin, Allan F. Pyesmany, Nyla A. Heerema, Cheryl Edens, Paul S. Gaynon
Journal: Blood (2006)
The G Protein-Coupled Receptor cysLT1 Signals Via ERK/MAP-Kinase and Pyk2, but Not NF-kappa B, in CD34+ Progenitor Cells, Explaining Its Dual Effect on Both, Cell Migration and Proliferation.
Authors: Andreas M. Boehmler, Gabriele Seitz, Lothar Kanz, Robert Möhle
Journal: Blood (2005)
A Combined Evaluation of Severity, Presentation and Duration of Chronic GvHD Predicts Transplant Outcome Among Patients with a Hematological Malignancy Undergoing Allogeneic Stem Cell Transplantation
Authors: Roberto Crocchiolo, Colombe Saillard, Sabine Furst, Jean El-Cheikh, Luca Castagna, Catherine Faucher, Claire Oudin, Samia Harbi, Angela Granata, Christian Chabannon, Didier Blaise
Journal: Blood (2011)
EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis
Authors: Ioanna Triviai, Thomas Stuebig, Anita Badbaran, Silke Zeschke, Victoria Panagiota, Michael Heuser, Carol Stocking, Nicolaus Kroger
Journal: Blood (2014)
gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Authors: M.R. Mirza, B.J. Monk, A. Oza, S. Mahner, A. Redondo, M. Fabbro, J. Ledermann, D. Lorusso, I.B. Vergote, O. Rosengarten, J. Berek, J. Herrstedt, A.V. Tinker, A. Dubois, A. Gonzalez Martin, P. Follana, B. Benigno, B.J. Rimel, S. Agarwal, U. Matulonis
Journal: Annals of Oncology (2016)
Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma.
Authors: Lan V. Pham, Archito T. Tamayo, Linda C. Yoshimura, Waldeman Priebe, Nicholas J. Donato, Moshe Talpaz, Richard J. Ford
Journal: Blood (2006)
Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation
Authors: Nicole Jacobi, Regine Grosse, Tugce Aktas, Lena Herich, Peter Nielsen, Roland Fischer, Tatjana Zabelina, Ulrike Bacher, Nicolaus Kroeger
Journal: Blood (2011)
High Rate of BCR-ABL Transcript Undetectability Achieved by Treating with Imatinib Mesylate Very Late CML Patients in Stable CCR after IFN.
Authors: Alimena Giuliana, Diverio Daniela, Breccia Massimo, Mancini Marco, Giuliani Nicoletta, Latagliata Roberto, Nanni Mauro, Mandelli Franco
Journal: Blood (2004)
Bestowing Transient Cytotoxic Capability on Dendritic Cells by Transfection with In Vitro Transcribed (IVT) TRAIL mRNA.
Authors: Norihiro Watanabe, Miwako Narita, Toshio Yano, Naoko Sato, Asuka Sekiguchi, Anri Saito, Ayumi Yokoyama, Flavio Ayres, Louie Alldawi, Tatsuo Furukawa, Ken Toba, Yoko Watanabe, Yoshiaki Takahashi, Masuhiro Takahashi
Journal: Blood (2004)
Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.
Authors: Heike Pfeifer, Barbara Wassmann, Anni Pavlova, Martin Mueller, Lydia Wunderle, Patrick Brueck, Johannes Oldenburg, Andreas Hochhaus, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann
Journal: Blood (2005)
Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation
Authors: Ezhil Pavai Mohanan, John C Panetta, Kavitha M Lakshmi, Fouzia NA, Abhijeet Ganapule, Aby Abraham, Auro Viswabandya, Alok Srivastava, Vikram Mathews, Biju George, Poonkuzhali Balasubramanian
Journal: Blood (2014)
Cancer Detection in Human Tissue Samples Using a Fiber-Tip pH Probe
Authors: Erik P. Schartner, Matthew R. Henderson, Malcolm Purdey, Deepak Dhatrak, Tanya M. Monro, P. Grantley Gill, David F. Callen
Journal: Cancer Research (2016)

Abstract Intraoperative detection of tumorous tissue is an important unresolved issue for cancer surgery. Difficulty in differentiating between tissue types commonly results in the requirement for additional surgeries to excise unremoved cancer tissue or alternatively in the removal of excess amounts of healthy tissue. Although pathologic methods exist to determine tissue type during surgery, these methods can compromise postoperative pathology, have a lag of minutes to hours before the surgeon receives the results of the tissue analysis, and are restricted to excised tissue. In this work, we report the development of an optical fiber probe that could potentially find use as an aid for margin detection during surgery. A fluorophore-doped polymer coating is deposited on the tip of an optical fiber, which can then be used to record the pH by monitoring the emission spectra from this dye. By measuring the tissue pH and comparing with the values from regular tissue, the tissue type can be determined quickly and accurately. The use of a novel lift-and-measure technique allows for these measurements to be performed without influence from the inherent autofluorescence that commonly affects fluorescence-based measurements on biological samples. The probe developed here shows strong potential for use during surgery, as the probe design can be readily adapted to a low-cost portable configuration, which could find use in the operating theater. Use of this probe in surgery either on excised or in vivo tissue has the potential to improve success rates for complete removal of cancers. Cancer Res; 76(23); 6795–801. ©2016 AACR.
Lifestyle Advice Combined with Personalized Estimates of Genetic or Phenotypic Risk of Type 2 Diabetes, and Objectively Measured Physical Activity: A Randomized Controlled Trial
Authors: Job G. Godino, Esther M. F. van Sluijs, Theresa M. Marteau, Stephen Sutton, Stephen J. Sharp, Simon J. Griffin
Journal: PLoS Medicine (2016)

Background Information about genetic and phenotypic risk of type 2 diabetes is now widely available and is being incorporated into disease prevention programs. Whether such information motivates behavior change or has adverse effects is uncertain. We examined the effect of communicating an estimate of genetic or phenotypic risk of type 2 diabetes in a parallel group, open, randomized controlled trial. Methods and Findings We recruited 569 healthy middle-aged adults from the Fenland Study, an ongoing population-based, observational study in the east of England (Cambridgeshire, UK). We used a computer-generated random list to assign participants in blocks of six to receive either standard lifestyle advice alone (control group, n = 190) or in combination with a genetic (n = 189) or a phenotypic (n = 190) risk estimate for type 2 diabetes (intervention groups). After 8 wk, we measured the primary outcome, objectively measured physical activity (kJ/kg/day), and also measured several secondary outcomes (including self-reported diet, self-reported weight, worry, anxiety, and perceived risk). The study was powered to detect a between-group difference of 4.1 kJ/kg/d at follow-up. 557 (98%) participants completed the trial. There were no significant intervention effects on physical activity (difference in adjusted mean change from baseline: genetic risk group versus control group 0.85 kJ/kg/d (95% CI −2.07 to 3.77, p = 0.57); phenotypic risk group versus control group 1.32 (95% CI −1.61 to 4.25, p = 0.38); and genetic risk group versus phenotypic risk group −0.47 (95% CI −3.40 to 2.46, p = 0.75). No significant differences in self-reported diet, self-reported weight, worry, and anxiety were observed between trial groups. Estimates of perceived risk were significantly more accurate among those who received risk information than among those who did not. Key limitations include the recruitment of a sample that may not be representative of the UK population, use of self-reported secondary outcome measures, and a short follow-up period. Conclusions In this study, we did not observe short-term changes in behavior associated with the communication of an estimate of genetic or phenotypic risk of type 2 diabetes. We also did not observe changes in worry or anxiety in the study population. Additional research is needed to investigate the conditions under which risk information might enhance preventive strategies. (Current Controlled Trials ISRCTN09650496; Date applied: April 4, 2011; Date assigned: June 10, 2011). Trial Registration The trial is registered with Current Controlled Trials, ISRCTN09650496.
Response to: ‘Criteria for CAPS, is it all in the name?’ by Touitou and Sarrabay
Authors: Jasmin B Kuemmerle-Deschner, Susanne M Benseler
Journal: Annals of the Rheumatic Diseases (2016)

We thank the authors of the eletter ‘Criteria for CAPS, is it all in the name?’1 for her very thoughtful comments on how to best define and name the autoinflammatory diseases we currently call cryopyrin-associated periodic syndromes—CAPS. The author very eloquently elaborate on some of the challenges we face when caring for children and adults with autoinflammatory diseases. Traditionally, disease names have highlighted the specific clinical phenotype—familiar cold-induced urticaria—or marked the name …
Neurogenic Megacolon in Spinal Cord Injury
Authors: Rukma R Govindu, Michelle Kelley
Journal: New England Journal of Medicine (2016)

A 44-year-old man with quadriplegia presented with symptoms of urinary tract infection. Extremely large, intermittent waves of peristalsis, shown in a video, were noted. CT revealed massive dilatation of the transverse, descending, and sigmoid colon.
Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis
Authors: Reem Diri, Ali McBride, Christopher Lee, Alaa Bagalagel, Hussain Bakhsh, Daniel O. Persky, Karen MacDonald, Jennifer Martin, Ivo Abraham
Journal: Blood (2015)
Excess Reduction of Anthracyclines Results in Inferior Event-Free Survival in Core Binding Factor Acute Myeloid Leukemia in Children; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
Authors: Daisuke Tomizawa, Akio Tawa, Tomoyuki Watanabe, Akiko Moriya Saito, Kazuko Kudo, Takashi Taga, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Hiroyuki Takahashi, Hideki Nakayama, Katsuyoshi Koh, Hisato Kigasawa, Yoshiyuki Kosaka, Hayato Miyachi, Keizo Horibe, Tatsutoshi Nakahata, Souichi Adachi
Journal: Blood (2012)
Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase
Authors: Nadine Müller-Calleja, Davit Manukyan, Antje Canisius, Dennis Strand, Karl J Lackner
Journal: Annals of the Rheumatic Diseases (2016)

Hydroxychloroquine (HCQ) has been used for decades to treat patients with rheumatic diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis or the antiphospholipid syndrome (APS). We hypothesise that HCQ might target endosomal NADPH oxidase (NOX), which is involved in the signal transduction of cytokines as well as antiphospholipid antibodies (aPL).For in vitro experiments, monocytic cells were stimulated with tumour necrosis factor α (TNFα), interleukin-1β (IL-1β) or a human monoclonal aPL and the activity of NOX was determined by flow cytometry. The expression of genes known to be induced by these stimuli was quantified by quantitative reverse transcription PCR. Live cell imaging was performed by confocal laser scanning microscopy. Finally, the effects of HCQ on NOX-induced signal transduction were analysed in an in vivo model of venous thrombosis.HCQ strongly reduces or completely prevents the induction of endosomal NOX by TNFα, IL-1β and aPL in human monocytes and MonoMac1 cells. As a consequence, induction of downstream genes by these stimuli is reduced or abrogated. This effect of HCQ is not mediated by direct interference with the agonists but by inhibiting the translocation of the catalytic subunit of NOX2 (gp91phox) into the endosome. In vivo, HCQ protects mice from aPL-induced and NOX2-mediated thrombus formation.We describe here a novel mechanism of action of HCQ, that is, interference with the assembly of endosomal NOX2. Since endosomal NOX2 is involved in many inflammatory and prothrombotic signalling pathways, this activity of HCQ might explain many of its beneficial effects in rheumatic diseases including the APS.
MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.
Authors: Francis Giles, Steven J. Freedman, Alan Xiao, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Steven M. Kornblau, Susan O’Brien, Donald A. Bergstrom, David A. Rizzieri
Journal: Blood (2006)
Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia
Authors: Samantha L Savage, Christopher A. Eide, Kyle F Concannon, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Julia Elizabeth Maxson, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker
Journal: Blood (2015)
Prolonged Survival in Philadelphia Positive Acute Lymphoblastic Leukemia Treated with Autologus Stem Cell Transplantation in the Inhibitor Tyrosine Kinase Era : A Retrospective Study
Authors: Camille Favennec, Marie-Lorraine Chretien, Caroline Legouge, Jean-Noel M. Bastie, Denis Caillot
Journal: Blood (2015)
High Expression of Mir-9 down-Regulates the Poor Outcome Prognosticator ERG and Associates with Reduced Relapse-Rates in Acute Myeloid Leukemia
Authors: Heike Weidner, Marius Bill, Laura Schmalbrock, Madlen Jentzsch, Laura Kloss, Taqiuddine Gaber, Lynn Bonifacio, Karoline Schubert, Kathrin Wildenberger, Dennis Gerloff, Vladan Vucinic, Georg-Nikolaus Franke, Thoralf Lange, Michael Cross, Stephan Fricke, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind
Journal: Blood (2014)